Fig 1: miR-190b expression is increased, whereas FOXP2 expression is decreased in CRC cell lines. (A) miR-190b expression and (B) FOXP2 expression was examined in HT29, SW480, SW620 cells and the normal colon epithelial cell line, FHC. **P<0.01, ***P<0.001 vs. FHC. CRC, colorectal cancer; miR-190b, microRNA-190b; FOXP2, forkhead box protein P2.
Fig 2: FOXP2 is involved in miR-190b-mediated alterations to CRC cell behavior. FOXP2 (A) mRNA and (B) protein expression levels were reduced in cells transfected with si-FOXP2, and increased in cells transfected with the FOXP2 overexpression vector. (C) Cell proliferation, (D) colony formation, (E) cell invasion (×200) and (F) cell apoptosis in colorectal cancer cell transfected with si-FOXP2, NC-siRNA, si-FOXP2 and miR-190b inhibitor, pcDNA3.1, or pFOXP2. *P<0.05, **P<0.01, ***P<0.001. miR-190b, microRNA-190b; FOXP2, forkhead box protein P2; si, small interfering; NC, negative control.
Fig 3: FOXP2 is a direct target of miR-190b. (A) A conserved binding site within the 3'-UTR of FOXP2 for miR-190b was identified. (B) Downregulation of miR-190b significantly increased the luciferase activity of pGL3-FOXP2-wt, but not pGL3-FOXP2-mut. (C) Downregulation of miR-190b appeared to increase the expression of FOXP2 in colorectal cancer cells. ***P<0.001 vs. respective NC inhibitor. miR-190b, microRNA-190b; FOXP2, forkhead box protein P2; UTR, untranslated region; wt, wild-type; mut, mutant; NC, negative control.
Supplier Page from Abcam for Anti-FOXP2 antibody